company background image
2196 logo

Shanghai Fosun Pharmaceutical (Group) SEHK:2196 Stock Report

Last Price

HK$14.54

Market Cap

HK$67.4b

7D

1.1%

1Y

-11.8%

Updated

09 Dec, 2024

Data

Company Financials +

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SEHK:2196 Stock Report

Market Cap: HK$67.4b

2196 Stock Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details

2196 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥14.54
52 Week HighCN¥19.50
52 Week LowCN¥11.32
Beta0.72
11 Month Change-6.19%
3 Month Change23.43%
1 Year Change-11.77%
33 Year Change-60.33%
5 Year Change-35.23%
Change since IPO34.13%

Recent News & Updates

Recent updates

Shareholder Returns

2196HK PharmaceuticalsHK Market
7D1.1%-0.2%3.1%
1Y-11.8%-2.7%19.6%

Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: 2196 underperformed the Hong Kong Market which returned 19.6% over the past year.

Price Volatility

Is 2196's price volatile compared to industry and market?
2196 volatility
2196 Average Weekly Movement8.8%
Pharmaceuticals Industry Average Movement6.7%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 2196 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2196's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199439,309Deyong Wenwww.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
2196 fundamental statistics
Market capHK$67.44b
Earnings (TTM)HK$2.26b
Revenue (TTM)HK$44.47b

33.1x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2196 income statement (TTM)
RevenueCN¥41.61b
Cost of RevenueCN¥21.83b
Gross ProfitCN¥19.78b
Other ExpensesCN¥17.67b
EarningsCN¥2.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.79
Gross Margin47.55%
Net Profit Margin5.08%
Debt/Equity Ratio55.0%

How did 2196 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

34%

Payout Ratio